Unraveling structural requirements of amino-pyrimidine T790M/L858R double mutant EGFR inhibitors: 2D and 3D QSAR study

被引:3
|
作者
Fatima, Shehnaz [1 ]
Agarwal, Subhash Mohan [1 ]
机构
[1] ICMR Natl Inst Canc Prevent & Res, Bioinformat Div, 1-7,Sect 39, Noida 201301, India
关键词
EGFR; double mutant inhibitor; QSAR; TMLR; CELL LUNG-CANCER; DRUG-RESISTANCE; MODEL; MUTATION; DESIGN;
D O I
10.1080/10799893.2018.1494740
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
EGFR is an important drug target in cancer. However, the ineffectiveness of first generation inhibitors due to the occurrence of a secondary mutation (T790M) results in the relapse of the disease. Identification of reversible inhibitors against T790M/L858R double mutants (TMLR) thus is a foremost requirement. In this study, various 2 D and 3 D Quantitative Structure-Activity Relationship models were built for amino-pyrimidine compounds with their known biological activity against TMLR mutants. The model developed using multiple linear regression statistical method via stepwise forward-backward variable selection technique showed the best results in terms of internal and external predictivity. The 2D-QSAR model indicated that the presence of electronegative atom, H-bond donors, moderate slogp, count of number of N atoms separated from O (T_N_O_4), 4pathClusterCount and number of S atom connected with two single bonds (SssSE-index), is required for increasing the inhibitory potential of compounds. Also, the 3D-QSAR model suggested that electronegative group at certain positions along with the presence of bulky groups is beneficial for good inhibition activity of the compounds. Thus, the QSAR models developed in the present work can be used for predicting the TMLR bioactivity of a new series of amino-pyrimidine derivatives. To the best of the author's knowledge, this is the first study which deals with the development of 2 D and 3D-QSAR models for double mutant TMLR inhibitors.
引用
收藏
页码:299 / 306
页数:8
相关论文
共 50 条
  • [31] Case report of three EGFR TKI naive lung adenocarcinoma containing double EGFR mutations (L858R/T790M or Exon 19 Deletion/T790M); Comparing genetic information and histology
    Sakashita, Shingo
    Shiba-Ishii, Aya
    Murata, Yoshihiko
    Sekimoto, Ryutaro
    Minami, Yuko
    Sato, Yukio
    Noguchi, Masayuki
    PATHOLOGY RESEARCH AND PRACTICE, 2018, 214 (08) : 1224 - 1230
  • [32] Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M)
    Shaheen, Mennatallah A.
    El-Emam, Ali A.
    El-Gohary, Nadia S.
    BIOORGANIC CHEMISTRY, 2020, 105
  • [33] A systematic pipeline of protein structure selection for computer-aided drug discovery: A case study on T790M/L858R mutant EGFR structures
    Das, Agneesh Pratim
    Nandekar, Prajwal
    Mathur, Puniti
    Agarwal, Subhash M.
    PROTEIN SCIENCE, 2023, 32 (09)
  • [34] A High-throughput Cell-based Screening for L858R/T790M Mutant Epidermal Growth Factor Receptor Inhibitors
    Lin, Wen-Hsing
    Song, Jen-Shin
    Lien, Tzu-Wen
    Chang, Chun-Yu
    Wu, Szu-Huei
    Huang, Yu-Wen
    Chang, Teng-Yuan
    Fang, Ming-Yu
    Yen, Kuei-Jung
    Chen, Chun-Hwa
    Chu, Chang-Ying
    Hsieh, Hsing-Pang
    Chen, Yi-Rong
    Chao, Yu-Sheng
    Hsu, John T-A
    ANTICANCER RESEARCH, 2012, 32 (01) : 147 - 151
  • [35] Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer
    Wang, Xiaoxue
    Qin, Zhongxiang
    Qiu, Wenrui
    Xu, Kejia
    Bai, Yuting
    Zeng, Beilei
    Ma, Yakun
    Yang, Shuang
    Shi, Yi
    Fan, Yan
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 277
  • [36] Design, Synthesis and Assessment of Novel Molecule against Drug-Resistant Dual Mutant EGFR (T790M/ L858R) to Treat NSCLC
    Kumar, V.
    Gholap, S. L.
    Sehgal, D.
    Inampudi, K. K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S347 - S347
  • [37] The discovery of a potent and selective third-generation EGFR kinase inhibitor as a therapy for EGFR L858R/T790M double mutant non-small cell lung cancer
    An, Baijiao
    Pan, Tingting
    Hu, Jinhui
    Pang, Yanqing
    Huang, Ling
    Chan, Albert S. C.
    Li, Xingshu
    Yan, Jun
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 183
  • [38] Design and investigation of novel iridoid-based peptide conjugates for targeting EGFR and its mutants L858R and T790M/L858R/C797S: an in silico study
    Das, Amrita
    Biggs, Mary A.
    Hunt, Hannah L.
    Mahabadi, Vida
    Goncalves, Beatriz G.
    Phan, Chau Anh N.
    Banerjee, Ipsita A.
    MOLECULAR DIVERSITY, 2024,
  • [39] Potent, novel small molecule inhibitors targeting EGFR L858R/T790M mutation for non-small cell lung cancer
    Sivanandhan, Dhanalakshmi
    Parikh, Payal K.
    Sheshachalam, Avinash
    Chandregowda, V
    Bhakthavatchalam, Rajagopal
    Gupta, Manish
    Giri, Sanjeev
    Krishnakumar, V
    CANCER RESEARCH, 2014, 74 (19)
  • [40] Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants
    Zhang, Haoyang
    Wu, Wenkui
    Feng, Chao
    Liu, Zhaogang
    Bai, Enhe
    Wang, Xueyuan
    Lei, Meng
    Cheng, Hao
    Feng, Huayun
    Shi, Jingmiao
    Wang, Jia
    Zhang, Zhao
    Jin, Tao
    Chen, Shanshan
    Hu, Shihe
    Zhu, Yongqiang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 135 : 12 - 23